Articles tagged with Parkinsons Disease
A new prototype for wearable tremor suppression gloves has been developed by Western University researchers, which tracks voluntary movement to minimize tremors. The gloves will be custom designed for both hands of each patient to maximize benefits.
A University of Guelph study found that cardiolipin helps prevent protein misfolding in Parkinson's disease, leading to nerve cell death. Researchers believe cardiolipin may represent a new target for developing therapies to slow the progression of the disease.
Researchers discovered that levels of alpha-synuclein protein are decreased in people with Parkinson's disease, while levels of oligomeric alpha-synuclein are increased. This finding suggests that tears could be a reliable biological marker for the disease.
Researchers developed a high-resolution nanometer-scale magnetic resonance imaging (MRI) technique, enabling unprecedented views of biological systems. The new method extends traditional MRI capabilities to the nanoscale, providing insights into Parkinson's and Alzheimer's diseases.
A study published in Movement Disorders found that lower levels of alpha-synuclein protein in cerebrospinal fluid are associated with postural instability and gait difficulty in Parkinson's disease patients. The study also suggests that lower beta-amyloid levels may be related to memory problems in Parkinson's patients.
Excess calcium levels can lead to the formation of toxic clusters with alpha-synuclein, causing brain cell death. Understanding this interaction may aid in developing new treatments for Parkinson's disease.
Researchers discovered that individual neurons fight back to maintain signaling between brain regions, slowing disease progression in glaucoma. This finding suggests a potential new therapeutic approach to preserve vision and slow degeneration in age-related neurodegenerative disorders.
Researchers found that an unexpected sound increased brainwave activity and improved stopping outcomes by up to 15%. The study offers insight into the brain's communication with the motor system and could lead to new treatments for motor-control disorders like Parkinson's disease and ADHD.
Researchers developed a rapid test to diagnose Parkinson's and dementia with Lewy bodies using cerebral spinal fluid samples. The test showed high accuracy in detecting these diseases within two days, outperforming related assays.
Scientists have identified a new family of peptides in wasp venom that can control insect behavior, which may also help develop Parkinson's disease treatments. The peptides, called ampulexins, were found to immobilize cockroaches, and further research aims to identify cellular targets for potential treatment applications.
Researchers discovered that a 'puff' of dopamine before movement initiation is essential for normal motor function, not constant dopamine levels. This finding may lead to more effective treatments with fewer side effects for Parkinson's disease.
Researchers at Emory University have successfully tested a tactic for controlling dyskinesias in Parkinson's disease by reducing striatal projection neuron hyperactivity with NMDA receptor antagonists. The study aims to develop new treatment options with improved effectiveness for people with Parkinson's disease.
A study using fruit fly models reveals that a genetic mutation in the DNAJC13 gene leads to the accumulation of α-synuclein protein, causing motor dysfunction and neurodegeneration. This finding provides new insights into the molecular mechanisms of familial Parkinson's disease and may lead to the development of disease-modifying thera...
Parkinson's UK is providing over $1 million in funding to Neurolixis to accelerate the development of a promising new drug for people with Parkinson's. The project aims to address L-DOPA-induced dyskinesia, a disabling side effect of long-term L-DOPA treatment.
Researchers at the Buck Institute for Research on Aging have identified a potential therapeutic avenue for Parkinson's disease by clearing senescent astrocytes, which stop dividing and secrete deleterious factors. This approach shows promise in preventing symptoms of the incurable neurological disorder.
A new study from the University of Bergen shows that impairment in mitochondria may actually protect the brain in Parkinson's disease. Brain cells with decreased complex I levels are less likely to contain Lewy bodies, abnormal protein-aggregates that characterize Parkinson's disease.
A new study found that brains of people with Huntington's disease (HD) and Parkinson's disease (PD) show similar responses to a lifetime of neurodegeneration, despite being distinct diseases. Most genes related to immune response and inflammatory pathways are common in both diseases.
Researchers found the subthalamic nucleus is responsible for detecting unnatural android movements, similar to Parkinson's disease. This study improves understanding of both android design and Parkinson's pathology.
Researchers have found that patients with Parkinson's disease have more errors in mitochondrial DNA within the brainstem, leading to increased cell death. Surviving cells have higher copies of mitochondrial DNA, suggesting a new target for therapies.
Researchers found that people with Parkinson's disease had significantly lower caffeine levels in their blood, even if they consumed the same amount as those without the disease. The study suggests a simple test for early diagnosis could be developed using caffeine levels.
Researchers found that exercise increases DJ-1 protective gene expression, preventing abnormal protein accumulation in the brain. This may help slow Parkinson's disease progression.
A study of over 1,200 Veterans with Parkinson's disease found that those receiving deep brain stimulation (DBS) lived an average of 6.3 years after surgery, compared to 5.7 years for non-DBS patients. This modest survival advantage was attributed to improved quality of life and better symptom control.
Researchers at CRG discover a mechanism regulating alpha-synuclein protein linked to Parkinson's disease and multiple system atrophy (MSA). Two factors, TIAR and ELAVL1, are deemed crucial in neurodegeneration, offering potential biomarkers for early detection and new treatment targets.
Researchers developed a wearable robotic system to improve balance and gait in Parkinson's disease patients. After a single training session, both groups showed improved response to perturbations and increased gait stability.
Researchers at Tel Aviv University have identified a novel form of protein aggregation that is both reversible and has positive physiological consequences for cells. This discovery may lead to new treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
A large-scale genetic study has clarified the distinctive genetic signature of Dementia with Lewy bodies, a common type of dementia. The research found that DLB accounts for 10-15% of dementia cases, but its genetic profile is unique compared to Alzheimer's and Parkinson's diseases.
The study reveals how toxic oligomers disrupt brain cell membranes, creating defects that lead to neuronal death. Understanding this process offers an opportunity to develop new treatments for Parkinson's Disease.
A randomized clinical trial found that high-intensity exercise three times a week slows worsening of Parkinson's symptoms, while moderate intensity workouts have no effect. The study suggests that high-intensity exercise may be an effective treatment for delaying disease progression.
A team of MGH researchers has identified a genetic change that may cause the rare neurological disorder XDP, which combines features of dystonia and Parkinson's disease. The discovery reveals that a DNA sequence change, including an insertion of a retrotransposon, is correlated with the age of onset for the disease.
A new phase 2 trial found that high-intensity exercise can safely reduce worsening of motor symptoms in early-stage Parkinson's disease. Participants who exercised three times a week showed minimal decline in symptoms, while those who didn't exercise experienced significant worseness.
A new phase 2 trial found that high-intensity exercise three times a week for six months is safe and decreases worsening of motor symptoms in early-stage Parkinson's disease patients. The study compared high-intensity exercise to moderate intensity and found significant benefits for the high-intensity group.
Researchers from Aarhus University discovered that patients with Rapid Eye Movement Sleep Behaviour Disorder (RBD) lack dopamine and experience brain inflammation, which may lead to Parkinson's disease. This study provides new insights into the early stages of Parkinson's disease development.
A study by Penn Medicine found that women with Parkinson's disease are less likely to have caregivers compared to men, despite experiencing more psychological strain from caregiving. The disparity is attributed to women living longer than their potential caregivers and being more likely to be caregivers themselves.
A multidisciplinary neuroscience study found that low frequency brain stimulation of the subthalamic nucleus can improve cognitive symptoms in patients with Parkinson's disease. The research also reveals a new connection between the frontal cortex and the subthalamic nucleus, which may be targeted to improve cognitive function.
A new study suggests that combining Virtual Reality and treadmill exercise therapy can dramatically lower the incidence of falling among Parkinson's patients. The therapy promotes beneficial brain plasticity, even in patients with neurodegenerative disease, and enhances motor control and cognitive performance.
Researchers from TSRI have identified a process in nerve cells called the S-nitrosylation reaction that may contribute to Parkinson's disease. The study found that this reaction can trigger cell death by preventing the proper removal of damaged mitochondria, leading to neuronal damage and death.
A study has found a connection between genetic mutations in lysosomal storage disorders and an increased risk of developing Parkinson's disease. Researchers analyzed the largest available Parkinson's disease genetic dataset, discovering that nearly half of those with the disease carried damaging mutations in these genes.
Studies show that gut-derived metabolites may prevent neurodegeneration, while probiotic treatment corrects memory problems in an Alzheimer's mouse model. The research suggests targeting the gut could be a promising angle to tackle brain disorders across the lifespan.
The number of people with Parkinson's disease is expected to grow to 14.2 million by 2040 due to increasing life expectancy and population aging. The medical community must mobilize to respond to this growing public health threat, advocating for increased research funding, access to care, and affordable treatments.
A four-year study investigates how long-term exposure to airborne particulates relates to Parkinson's onset later in life, exploring the role of nasal inflammation and anti-inflammatory medications. The team aims to develop ways to evaluate an individual's risk for the disease and therapies to prevent or slow its progression.
A recent study by Korean researchers identified a potential mechanism of licorice extract inhibiting dopaminergic neuronal cell death in Parkinson's disease. The study found that liquiritigenin, a compound extracted from licorice, induces the expression of RNF146 protein and removes excessive PAR accumulation, resulting in inhibition o...
Researchers are investigating a novel treatment approach for Parkinson's disease by inhibiting the protein Bach1, which blocks the body's natural protection against oxidative stress. By removing Bach1, scientists aim to restore balance and promote the activation of neuroprotective genes.
A new study by OHSU researchers suggests that performing brain surgery on patients who are asleep can produce comparable or even better clinical outcomes than procedures conducted while the patient is awake. This approach has improved speech fluency and reduced motor function issues for patients undergoing deep-brain stimulation. The s...
A small pilot study found that focused ultrasound treatment improved hand tremor by up to 62% in participants with Parkinson's disease, with minimal side effects. Further research is needed to confirm the effectiveness and potential role of this scalpel-free surgery approach.
Researchers at City College of New York are exploring Sonic Hedgehog as a potential treatment for Parkinson's Disease. They have found that dopamine neurons secrete SHH, which can help reduce symptoms like dyskinesia, and are now testing Smoothened agonists in both mice and macaques.
Researchers found that LRRK2 is necessary for the survival of dopamine-containing neurons in the brain, which are affected by Parkinson's disease. The study could alter treatment approaches against the disease.
Scientists used a novel gene editing technique to uncover the genetic basis of paraquat-induced Parkinson's disease. The study identified three genes - POR, ATP7A and SLC45A4 - that confer resistance to paraquat, suggesting these genes may be responsible for the toxicity.
Researchers are studying the relationship between gut bacteria and Parkinson's disease, aiming to identify early signs of the illness. The study aims to compare the gut bacteria of people in the earliest stages of the disease with those who are healthy.
Researchers have unraveled a direct link between LRRK2 protein dimerization and genetic mutations in Parkinson's disease. This process could lead to a promising new therapy route, as the kinase inhibitor causes lung and kidney problems.
The study highlights the growing impact of neurological disorders on global health, with increased deaths and disabilities over the past 25 years. The most prevalent disorders are tension-type headaches, migraine, and Alzheimer's disease, which have seen significant increases in cases and DALYs.
Researchers at the University of Dundee have identified the 3D structure and inner workings of the PINK1 enzyme, a key player in protecting brain cells against stress. This breakthrough provides crucial insights into how PINK1 exerts its protective role in Parkinson's disease.
Research shows carbidopa, an FDA-approved Parkinson's disease drug, has anticancer properties. The study found that carbidopa significantly inhibits cancer cell growth in both human pancreatic cancer cells and mouse models, suggesting potential as an anticancer medication.
Researchers found Parkinson's disease reduces olfactory bulb glomerular volume by over half and alters their distribution, suggesting a key role for Lewy bodies in triggering the disease. The study provides new insights into the anatomical link between Parkinson's disease and impaired sense of smell.
A KAIST research team has identified a new mechanism that causes the hallmark symptoms of Parkinson's disease, including tremors. The discovery presents a new perspective on three decades of conventional wisdom and opens up new avenues for alleviating motor problems.
A computational study models the strength of basal ganglia connections between healthy and Parkinsonian brains, revealing a broad overlap in neural connection strengths. The research could lead to customized therapies specific to individual patterns of neural degeneration.
Research found disconnections in brain areas involved in attention and visual processing may contribute to visual hallucinations in individuals with Parkinson's disease. The study used fMRI to examine connectivity between brain areas, showing decreased synchronization in patients with visual hallucinations.
A study of 121 people with Parkinson's disease found that consuming three cups of coffee per day did not improve movement symptoms. The researchers concluded that caffeine cannot be recommended as therapy for movement symptoms of Parkinson's disease.
Researchers have discovered a novel molecular pathway that interacts with prion protein, triggering neuronal dysfunction and cognitive impairments in Parkinson's disease. The study provides new targets for therapeutic intervention.
Researchers discovered that alpha-synuclein, a protein involved in Parkinson's disease, blocks signals from the important brain growth factor BDNF. This 'tug of war' between alpha-synuclein and BDNF affects brain cells' survival and explains why dopamine-producing neurons are more vulnerable to degeneration.
Researchers found that Parkinson's disease may be caused by maladaptive brain rewiring in the subthalamic nucleus, leading to impaired movement. The study challenges the traditional understanding of brain dysfunction in Parkinson's disease.